Form 4: BridgeBio Director Sells Shares Under 10b5-1 Plan

BridgeBio Pharma Director Frank McCormick sold 1,641 shares of common stock for $65 per share on October 27, 2025, as part of a pre-arranged 10b5-1 plan.

Summary

• Frank McCormick, a Director of BridgeBio Pharma, Inc. (BBIO), reported a sale of common stock.
• The transaction occurred on October 27, 2025.
• A total of 1,641 shares of common stock were disposed of at a price of $65 per share.
• The total value of the shares sold was approximately $106,665.
• Following this transaction, McCormick directly beneficially owns 878,338 shares of common stock.
• Additionally, McCormick indirectly beneficially owns 83,275 shares through the Francis P. McCormick Rev Trust U/A DTD 1/27/2017.
• This sale was executed pursuant to a Rule 10b5-1 sales plan, which was adopted by McCormick on August 28, 2024.

Sentiment

Score: 5

Explanation: The sale of shares by a director, executed under a pre-arranged Rule 10b5-1 plan, is a routine and scheduled transaction that does not typically indicate a change in insider sentiment or company outlook.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 sales plan, indicating a scheduled and non-discretionary sale, which often mitigates concerns about insider sentiment.

Negatives

• The sale reduces the direct insider ownership of common stock by a director.

Risks

• While executed under a 10b5-1 plan, any insider selling, regardless of its nature, can sometimes be misinterpreted by the market as a signal of reduced confidence, potentially leading to short-term stock price volatility.

Future Outlook

This filing, a Form 4, does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is a routine disclosure and does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology sector.

Stakeholder Impact

• Shareholders: Minimal impact as the sale was pre-planned and relatively small in the context of the director's overall holdings and the company's market capitalization.

Key Dates

Recommendation

The sale of a relatively small number of shares by a director, executed under a pre-arranged 10b5-1 plan, is a routine event and does not typically signal a significant change in the company's fundamentals or warrant a change in investment recommendation.

Keywords

BridgeBio Pharma, BBIO, Form 4, Insider Transaction, Stock Sale, Director, Frank McCormick, 10b5-1 Plan